NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development and commercialization of small molecule drugs and recombinant proteins.


Player Avatar mdriver78 (61.69) Submitted: 12/22/2012 10:43:16 PM : Underperform Start Price: $10.56 NPSP Score: -9.14

The spike will decay from the announcement that the U.S. Food and Drug Administration (FDA) has approved Gattex (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex will be available in the first quarter of 2013. In the near term the share price will suffer until the market proves the revenue potential of the drug.

Featured Broker Partners